1 outine examination to her family doctor with abnormal liver function tests.

2 viremia (up to 109/mL) lasting 5--6 days and abnormal liver function tests.

3  and were significantly higher in those with abnormal liver function tests.

4 toacanthomas (34 [10%]), rash (30 [9%]), and abnormal liver function tests (38 [11%]) in the vemurafe

5 nalyses, the percentage of patients with any abnormal liver function test after baseline sampling was

6  remaining on CsA, whereas thrombocytopenia, abnormal liver function tests, and hypokalemia were repo

7 ng (for caspofungin) local phlebitis, fever, abnormal liver function tests, and mild haemolysis.

8                   Asymptomatic patients with abnormal liver function tests are common in the lipid cl

9                         For individuals with abnormal liver function tests, common causes of hepatiti

10 ignificantly greater (P < 0.05) incidence of abnormal liver function tests, diarrhea, hypokalemia, an

11 ed in 53% (N = 373) of 709 patients based on abnormal liver function tests, neutropenia, history of I

12                         Three volunteers had abnormal liver function test results temporally associat

13 n patients investigated for liver disease or abnormal liver function test results.

14                     Liver injury ranged from abnormal liver-function test results to rapidly progress

15                  Patients with XHIM who have abnormal liver function tests should be considered at in

16 s appropriate for paclitaxel therapy who had abnormal liver function tests were eligible.

17                                  Reliance on abnormal liver function tests will miss most patients wi